LINICAL SPAIN SLU
Desconocido
AML-VACCiN: Clinical development of a dendritic cell vaccine therapy for acute myeloid leukaemia
LINICAL SPAIN SLU
participó en un
H2020:
H2020-PHC-2014-2015
Eradicating minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) is an area of high unmet medical need. AML is a de...
2015-12-09 - 2020-09-30 | Financiado
2015-12-09 - 2020-09-30 | Financiado
GLORIA: Comparing the effectiveness and safety of additional low dose glucocorticoid in treatment strategies...
LINICAL SPAIN SLU
participó en un
H2020:
H2020-PHC-2014-2015
GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective an...
2015-04-08 - 2021-08-31 | Financiado
2015-04-08 - 2021-08-31 | Financiado
* No se disponen de datos de la empresa actual.